What Does Argireline Do? Mechanism, Human Trials and Limits

Start with our pillar guide: Peptide Ingredients in Skincare: Signal, Carrier, Neurotransmitter and Enzyme-Inhibitor Peptides Explained, or browse all Peptide Science articles.

Direct answer: What does Argireline do? Argireline (acetyl hexapeptide-8) is a lab-made peptide that mimics part of SNAP-25, a nerve protein needed to make muscles contract. In cell studies it weakly disrupts the same machinery Botox targets. Small human trials show modest smoothing around the eyes after about 4 weeks. Evidence: limited.

Argireline belongs to a group sometimes called neurotransmitter-inhibiting peptides. For how it compares with signal peptides like Matrixyl and carrier peptides like GHK-Cu, see our guide to peptide ingredients in skincare. This page is the hub for our Argireline coverage. It walks through what the molecule is, what the studies measured, and where the claims go further than the data.

Key takeaways

• Mechanism: In lab studies, Argireline interferes with SNARE complex formation and lowers neurotransmitter release. Botulinum toxin type A acts on the same machinery, but Argireline showed "much lower efficacy" (Blanes-Mira et al., 2002). Evidence: lab only, though widely cited.
• Wrinkles: The best independent-looking human data is 1 trial of 60 people over 4 weeks, published in 2 papers. Results were modest and partly subjective (Wang et al., 2013). Evidence: limited.
• Penetration: In an FDA lab study on human cadaver skin, 0.22% of the applied dose reached the stratum corneum (the outermost layer), 0.01% reached the epidermis, and none was detected in the dermis (Kraeling et al., 2015).
• "Works like Botox": No human study shows Argireline relaxes facial muscles the way an injected neurotoxin does. Evidence: not supported.
• Safety: Topical use looks low-risk in the small datasets available. Argireline is not approved for injection, and 1 published case of injection ended in a mycobacterial skin infection (Chen et al., 2021).

What is Argireline (acetyl hexapeptide-8)?

On ingredient labels, Argireline appears as acetyl hexapeptide-8. Older papers and some products use acetyl hexapeptide-3, which is an older name for the same molecule. "Argireline" is the trade name.

The sequence is 6 amino acids, written Ac-EEMQRR-NH2: acetylated glutamic acid, glutamic acid, methionine, glutamine, arginine and arginine, with an amide cap at the end (Blanes-Mira et al., 2002). The acetyl and amide caps are standard chemical tweaks meant to make short peptides more stable.

The EU's official cosmetic ingredient database, CosIng, describes acetyl hexapeptide-8 as a "synthetic peptide consisting of arginine, methionine, and acetylated glutamic acid residues." It lists 2 functions: humectant and skin conditioning. We checked the entry through the official EC search API on October 10, 2026. CosIng lists no anti-wrinkle or muscle-relaxing function. That doesn't prove the peptide does nothing to wrinkles, because CosIng records the cosmetic role of an ingredient and doesn't assess efficacy. It does mean the regulatory description stops well short of the marketing.

SNAP-8 is a related ingredient: an 8-amino-acid peptide that extends the Argireline sequence. We cover it in our SNAP-8 peptide explainer.

What does Argireline do? How it is supposed to work

The SNARE complex, in one paragraph

A nerve tells a muscle to contract by releasing acetylcholine, a chemical messenger. The release depends on the SNARE complex, a group of proteins that pulls the vesicle holding the messenger against the cell membrane so it can empty. SNAP-25 is 1 of the core proteins in that complex.

What the lab work showed

Argireline came out of a rational-design program in which researchers built short peptides modeled on a part of SNAP-25. The idea was that a decoy fragment could compete with the real protein and destabilize the complex. In that 2002 origin paper, the hexapeptide interfered with SNARE complex formation and stability and inhibited neurotransmitter release in vitro. Its potency was similar to botulinum toxin A, but its efficacy was "much lower" (Blanes-Mira et al., 2002). Evidence: lab only.

The difference between potency and efficacy matters here. Potency describes how much of a substance you need to see an effect. Efficacy describes how large the maximum effect can get. When a molecule is "similarly potent but much less efficacious," it starts acting at comparable concentrations but tops out far lower, so adding more won't close the gap with the toxin.

The paper is widely cited (183 citations on Semantic Scholar as of October 10, 2026). It also came from the research program behind the commercial ingredient, so it is a developer study. Funding details are not reported in the abstract.

A separate animal signal: collagen

The same group of Chinese researchers who ran the main human trial also tested topical Argireline twice daily for 6 weeks in mice aged with D-galactose. Type I collagen fibers increased (P<0.01) and type III decreased (P<0.05) (Wang et al., 2013, mouse study). Evidence: animal only. Mouse skin is thinner and more permeable than human skin, so this result doesn't tell you what happens on your face.

What does Argireline do in people? The human evidence

Here is every human study in our verified source set. It is a short list.

The origin study: "up to 30%"

The 2002 paper reports that a 10% oil-in-water emulsion applied by healthy women reduced wrinkle depth by "up to 30%" after 30 days (Blanes-Mira et al., 2002). The abstract doesn't report the number of participants or describe a control. "Up to" usually describes the best result in a group, so the average change was probably smaller. The study came from the developer side. Evidence: early / preliminary.

Supplier marketing materials also circulate percentage claims for Argireline. We couldn't match those figures to a peer-reviewed paper, so we treat them as unverified.

The main RCT: 60 people, 4 weeks, reported twice

The most-cited controlled trial randomized 60 Chinese participants 3:1 to Argireline or placebo. Both groups applied the product around the eyes twice daily for 4 weeks. The "total anti-wrinkle efficacy" was 48.9% in the Argireline group and 0% with placebo. On silicone replicas, which are molds of the skin surface, roughness parameters dropped significantly (p<0.01) with Argireline and didn't change with placebo (Wang et al., 2013). The abstract doesn't report the concentration or the funder.

2 cautions:

1. 48.9% is not a wrinkle-depth reduction. It is a subjective global rating, roughly the share of participants judged to have improved. Product pages that say "reduces wrinkles by 48.9%" misread it.
2. This is 1 trial, not 2. The same 60-person, 3:1, 4-week design with the same 48.9% figure also appears in a second paper that adds a mouse arm (Wang et al., 2013, second report). If an article counts these as independent trials, it has double-counted.

Evidence: limited.

Raikou 2017: a small factorial trial

24 healthy volunteers were split across 4 arms of about 6 people each: acetyl hexapeptide-3 plus tripeptide-10 citrulline, tripeptide-10 citrulline alone, acetyl hexapeptide-3 alone, or neither. The study ran for 60 days and measured skin microtopography and TEWL (transepidermal water loss, a barrier measure). Some pairwise comparisons were significant and others weren't. Acetyl hexapeptide-3 lowered TEWL, and the authors said the mechanism behind any synergy was unclear (Raikou et al., 2017). Funding is not reported in the abstract. Evidence: early / preliminary.

The TEWL result fits CosIng's "humectant, skin conditioning" listing better than it fits a muscle-relaxing story.

Aruan 2023: the only head-to-head trial

This double-blind RCT enrolled 21 Indonesian women aged 26–55 and assigned them to 1 of 3 creams: acetyl hexapeptide-3, palmitoyl pentapeptide-4 (Matrixyl), or placebo. Each was applied twice daily around the eyes for 8 weeks, targeting crow's feet. Outcomes included Corneometer (hydration), Tewameter (TEWL), Cutometer (elasticity), photos and a grading scale. Palmitoyl pentapeptide-4 did better than both Argireline and placebo (Aruan et al., 2023). The authors reported no conflicts of interest, called it an "initial study," and asked for larger samples and longer follow-up. Concentrations are not reported in the abstract. Evidence: early / preliminary.

With about 7 people per arm, a single trial can't settle the comparison. We go through it in detail in Argireline vs Matrixyl.

Multi-ingredient serums: real results, unclear credit

L'Oréal R&I researchers tested a serum combining acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract. Across 2 clinical studies (n=50 for static wrinkles, n=42 for dynamic wrinkles) over 12 weeks, static wrinkle scores improved 35–69% and dynamic wrinkle scores improved 10–13% (p<0.001), with changes visible in the first week (Zhu et al., 2026). The abstract describes no placebo arm. Because the serum has 5 actives, none of the effect can be attributed to Argireline specifically. Evidence: limited, and only for the whole formula.

A related journal supplement collected real-world experiences from 5 dermatologists and 2 surgeons who used a serum containing 2% acetyl hexapeptide-8, 2% dipeptide diaminobutyroyl benzylamide diacetate, 5% PHA, 5% niacinamide and 1% laminaria alongside Botox injections (Lupin et al., 2024). These are narrative case reports with no controls, and funding is not stated in the abstract. Evidence: early / preliminary.

For what photos can and can't show, see Argireline before and after.

The blepharospasm trial: the closest test of the "Botox" idea

If Argireline acted on the nerve–muscle junction, the place to see it would be people already on botulinum toxin. NIH/NINDS researchers, with co-authors from BCN Peptides, ran a double-blind placebo-controlled RCT in 24 patients with blepharospasm (involuntary eyelid spasm). All were receiving Botox and applied topical acetyl hexapeptide-8 or placebo daily. There were no significant adverse events. Time until symptoms returned to baseline showed only a trend: 3.7 months with the peptide vs 3.0 months with placebo, and the difference was not statistically significant. 4 of 12 patients in the active group had a considerable extension, ranging from 3.3 to 7.1 months (Lungu et al., 2013; registered as NCT00942851).

This was a medical study, not a cosmetic one, and it missed significance. A follow-up NINDS trial (NCT01750346) was terminated at 8 participants. Evidence: early / preliminary, and not significant.

Can Argireline reach the muscle? The penetration problem

For a topical peptide to relax a muscle, it has to get through the stratum corneum and the epidermis, through the dermis, and into the nerve endings that sit beneath it. This step is where the Botox comparison runs into the most trouble. For background on why peptides struggle to get through, see do peptides absorb into skin?.

The FDA cadaver-skin study

Researchers at the US FDA's Center for Food Safety and Applied Nutrition put an oil-in-water emulsion containing 10% Ac-EEMQRR-amide on human cadaver skin and hairless guinea pig skin in diffusion cells, at 2 mg/cm², for 24 hours (Kraeling et al., 2015). Most of the peptide washed off the surface. In human skin:

• 0.22% of the applied dose was in the stratum corneum (0.54% in guinea pig skin)
• 0.01% was in the epidermis
• None was detected in the dermis or the receptor fluid below the skin
• No metabolites were detected

This is an in vitro model. Living skin has blood flow and repair processes that cadaver skin doesn't. Still, it is the most direct measurement available, and it was done by a regulator with no product to sell.

Formulation can change the numbers, somewhat

On pig ear skin, a water-in-oil-in-water multiple emulsion significantly increased penetration of acetyl hexapeptide-8 compared with simple oil-in-water and water-in-oil emulsions, and water-rich bases did better than oil-rich ones (Hoppel et al., 2015). The authors described the peptide's skin penetration as "sparsely studied and controversially discussed."

A 2018 study called Argireline's permeation "poor" and pointed to its large molecular weight, its hydrophilicity (it prefers water) and its zwitterionic charge (it carries both positive and negative charges). Chemically modified analogues permeated better in vitro (Lim et al., 2018). A 2022 review concluded that most anti-wrinkle peptides are poor candidates for skin permeation (Mortazavi & Moghimi, 2022), and a 2025 review stated that "the ability of AH-8 to reach neuromuscular junctions remains uncertain" (Zdrada-Nowak et al., 2025).

So what explains the smoother replicas in the Wang trial? We don't know. Surface effects are 1 possibility: the humectant and conditioning action listed in CosIng, plus the hydration and TEWL changes seen in Raikou. No study has tested that explanation directly, and none has shown a muscle effect in people.

Is Argireline safe?

Topical use. The origin paper reported no oral toxicity and no primary irritation at high doses (Blanes-Mira et al., 2002). The blepharospasm RCT reported no significant adverse events in 24 patients (Lungu et al., 2013). These datasets are small, and none followed users for longer than a few months.

Cell studies. An independent lab tested Argireline on 3 cell lines: HEK-293 kidney cells, IMR-32 neuroblastoma cells and human skin fibroblasts. It had a dose-dependent antiproliferative effect, meaning it slowed cell growth. Significant cytotoxicity appeared only at concentrations 18 to 10,000 times higher than those of doxorubicin, the reference cytotoxic drug (Grosicki et al., 2014). The authors noted how little independent cytotoxicity data existed. Evidence: lab only. A cell dish doesn't model the tiny fraction of a dose that gets into living skin.

Injection. Argireline is a cosmetic ingredient and is not approved for injection. A published case describes a 45-year-old woman who had Argireline injected into her forehead and temples. Within 1 week she developed redness, nodules and abscesses, and Mycobacterium abscessus infection was confirmed. She needed 5 months of clarithromycin plus moxifloxacin (Chen et al., 2021). If someone offers to inject Argireline, treat that as a red flag.

Are there registered clinical trials of Argireline?

We checked ClinicalTrials.gov through its API on October 10, 2026.

The most important gap is NCT01381484. A 70-person wrinkle trial registered with triple masking would be larger than any published Argireline wrinkle RCT. It finished in 2009, it has no posted results, and the Researcher found no linked publication. We can't tell you what it found. Unreported results can skew the published record, because positive findings are more likely to get written up.

Why is Argireline called "Botox in a bottle"?

An analysis of US Google search volume from 2013 to 2023 found that searches for both "Argireline" and "Botox in a Bottle" rose substantially in 2022. Argireline was still searched far less than Botox (Olsson et al., 2024). Asking whether Argireline is Botox in a bottle also comes up repeatedly in skincare communities.

The phrase sticks because both act on the SNARE machinery. The comparison breaks down on 3 counts: Argireline's lab efficacy is much lower, there is no evidence it reaches the nerve–muscle junction through skin, and no human trial shows muscle relaxation. Evidence for "works like Botox": not supported.

Can you use Argireline with Botox, retinol or other ingredients?

No study has tested how Argireline interacts with any of the products below. What follows is what the existing data does and doesn't say, and should not be read as a protocol.

With Botox or Dysport

People already on neurotoxins often ask whether a serum could extend the results. The only controlled data comes from the blepharospasm trial, which found a non-significant trend toward a longer effect (3.7 vs 3.0 months) (Lungu et al., 2013). The dermatologist case series with a multi-ingredient serum had no controls (Lupin et al., 2024). Ask your injector about timing around treatment days, since aftercare instructions differ between practices.

With copper peptides (GHK-Cu)

We found no published study combining acetyl hexapeptide-8 with GHK-Cu, whether as a test of interaction, stability or benefit. Our copper peptides guide covers what's known about GHK-Cu alone. Without data, the cautious approach is to watch for irritation if you add both. Don't assume the results add up.

With retinoids

No interaction data exists for Argireline with retinol or tretinoin either. Retinoids have a much deeper human evidence base for wrinkles than Argireline. If you're choosing where to spend your routine's tolerance, that difference matters more than any theoretical interaction. Prescription retinoid decisions belong with a clinician.

With Matrixyl

People often stack Argireline with Matrixyl or Matrixyl 3000, and a common question is which to use on the forehead and which under the eyes. The only direct comparison favored palmitoyl pentapeptide-4 around the eyes over 8 weeks in 21 women (Aruan et al., 2023). No trial has tested the 2 together.

Concentration and formula

Published studies used 10% in emulsions (Blanes-Mira et al., 2002; Kraeling et al., 2015) and 2% in a multi-ingredient serum (Lupin et al., 2024). The main RCT didn't report its concentration in the abstract. Lab data suggests water-rich and multiple-emulsion bases penetrate better than oil-rich ones (Hoppel et al., 2015). Whether that changes visible results hasn't been tested. Routine questions such as applying to damp skin or after toner have no study behind them either way.

Where the evidence stops

• No adequately powered, independent, long-term trial. The largest published wrinkle RCT had 60 people over 4 weeks, with an unreported concentration and funder.
• The largest registered trial is unreported. NCT01381484 (n=70) completed in 2009 with no results.
• No in vivo penetration data in humans. The best measurement is cadaver skin, and it found no peptide in the dermis.
• No evidence of muscle relaxation in people. The 1 study designed to look for a neurotoxin-like effect showed only a non-significant trend.
• Mechanism for the observed smoothing is unknown. Hydration and barrier effects are plausible but untested as the explanation.
• No interaction data with Botox, copper peptides, retinoids or Matrixyl.
• No long-term safety data beyond a few months of topical use.

FAQ

Is Argireline Botox in a bottle?

No. In lab tests it disrupts the same SNARE machinery as botulinum toxin A, but with "much lower efficacy" (Blanes-Mira et al., 2002), and in human cadaver skin none reached the dermis (Kraeling et al., 2015). No human study shows it relaxes facial muscles.

Can I use Argireline with Botox or Dysport?

No study shows harm, and the only controlled data (in blepharospasm patients) found a non-significant trend toward a longer Botox effect (Lungu et al., 2013). Nobody has tested it with Dysport. Ask your injector how to handle topical products around treatment days.

Will Argireline make my skin sag or make it dependent?

No published study reports sagging, rebound or "dependence" from topical Argireline. The available trials also ran for only 4 to 12 weeks, so long-term effects haven't been studied. Given how little appears to get past the outer skin layers (Kraeling et al., 2015), a muscle-weakening effect from topical use has not been shown.

Can I use Argireline with copper peptides or retinol?

There is no interaction data for either combination. Many people use them together, but whether they help each other, interfere or have no interaction hasn't been tested. If you add several actives at once and get irritation, you won't know which one caused it, so introducing them one at a time makes that easier to work out.

Why do my lines look worse after starting Argireline?

A recurring pattern in skincare forums is people saying their forehead, frown or under-eye lines looked deeper within days to about 2 weeks of starting, and in some accounts improved after they stopped. No study has examined or explained this. Possible confounders include changes in skin hydration, a water-based serum drying down on the surface, and differences in lighting or expression between photos. If you're concerned, stop using the product and see a dermatologist.

How long does Argireline take to work?

The main RCT measured results at 4 weeks (Wang et al., 2013), and the origin study at 30 days (Blanes-Mira et al., 2002). A multi-ingredient serum showed changes within the first week, but that can't be credited to Argireline alone (Zhu et al., 2026).

Go deeper: the Argireline cluster

• Peptide ingredients in skincare: the full guide
• Argireline before and after: what photos can and can't show
• Argireline vs Matrixyl: the only head-to-head trial
• SNAP-8 peptide: the longer cousin of Argireline
• Do peptides absorb into skin?
• Copper peptides for skin

References

Titles are summarized. The full title of each paper is on its PubMed record.

1. Blanes-Mira C, et al. Int J Cosmet Sci. 2002. Rational design of the acetyl hexapeptide (Ac-EEMQRR-NH2): in vitro SNARE/neurotransmitter-release work and a 30-day human application study (n not reported in abstract); developer study. https://pubmed.ncbi.nlm.nih.gov/18498523/
2. Wang Y, et al. Am J Clin Dermatol. 2013. Placebo-controlled RCT, n=60 (3:1), periorbital, 4 weeks. https://pubmed.ncbi.nlm.nih.gov/23417317/
3. Wang Y, et al. J Cosmet Laser Ther. 2013. Second report of the same 60-person trial, plus an aged-mouse arm. https://pubmed.ncbi.nlm.nih.gov/23607739/
4. Wang Y, et al. J Cosmet Laser Ther. 2013. D-galactose aged mice, topical Argireline, 6 weeks; animal study. https://pubmed.ncbi.nlm.nih.gov/23464592/
5. Lungu C, et al. Eur J Neurol. 2013. Double-blind placebo-controlled RCT, n=24, blepharospasm patients on Botox; NIH/NINDS with BCN Peptides co-authors. https://pubmed.ncbi.nlm.nih.gov/23146065/
6. Kraeling ME, et al. Cutan Ocul Toxicol. 2015. In vitro diffusion-cell penetration, human cadaver and hairless guinea pig skin, 10% emulsion, 24 h; US FDA authors. https://pubmed.ncbi.nlm.nih.gov/24754410/
7. Hoppel M, et al. Eur J Pharm Sci. 2015. Porcine ear skin penetration of acetyl hexapeptide-8 from different emulsion types; in vitro. https://pubmed.ncbi.nlm.nih.gov/25497319/
8. Lim SH, et al. Sci Rep. 2018. Argireline permeation and modified analogues; in vitro. https://pubmed.ncbi.nlm.nih.gov/29371611/
9. Zdrada-Nowak J, et al. Int J Mol Sci. 2025. Narrative review of acetyl hexapeptide-8. https://pubmed.ncbi.nlm.nih.gov/40565185/
10. Mortazavi SM, Moghimi HR. Int J Cosmet Sci. 2022. Review of skin permeation of anti-wrinkle peptides. https://pubmed.ncbi.nlm.nih.gov/35302659/
11. Grosicki M, et al. Acta Biochim Pol. 2014. Cytotoxicity in HEK-293, IMR-32 and human skin fibroblasts; in vitro. https://pubmed.ncbi.nlm.nih.gov/24644551/
12. Raikou V, et al. J Cosmet Dermatol. 2017. RCT, n=24, 4 arms, 60 days; acetyl hexapeptide-3 and tripeptide-10 citrulline. https://pubmed.ncbi.nlm.nih.gov/28150423/
13. Zhu M, et al. Int J Cosmet Sci. 2026. Ex vivo work plus 2 clinical studies (n=50, n=42), 12 weeks, multi-ingredient serum; L'Oréal R&I authors. https://pubmed.ncbi.nlm.nih.gov/41668671/
14. Lupin M, et al. J Drugs Dermatol. 2024 (supplement). Narrative case experiences from 7 clinicians using a 2% acetyl hexapeptide-8 multi-ingredient serum with Botox; uncontrolled. https://pubmed.ncbi.nlm.nih.gov/39496132/
15. Aruan RR, et al. J Clin Aesthet Dermatol. 2023. Double-blind RCT, n=21, 3 arms (AHP-3, PPP-4, placebo), 8 weeks, periorbital. https://pubmed.ncbi.nlm.nih.gov/36909866/
16. Chen CF, et al. World J Clin Cases. 2021. Case report: M. abscessus infection after Argireline injection, n=1. https://pubmed.ncbi.nlm.nih.gov/33748252/
17. Olsson SE, et al. JMIR Dermatol. 2024. US Google search volume analysis, 2013–2023. https://pubmed.ncbi.nlm.nih.gov/38376906/
18. European Commission. CosIng database entry: ACETYL HEXAPEPTIDE-8 (accessed via official EC search API, October 10, 2026). https://ec.europa.eu/growth/tools-databases/cosing/
19. ClinicalTrials.gov registry records NCT01381484, NCT00942851, NCT01750346, NCT02597777, NCT06143033 (accessed via API, October 10, 2026). https://clinicaltrials.gov/study/NCT01381484

Disclosure: This article contains no affiliate links, and no brand paid for or reviewed it. It is for general education and is not medical advice. For prescription treatments, injectables, or any skin reaction that worries you, talk to a board-certified dermatologist or another qualified clinician.

For educational purposes only; not medical advice. See our disclaimer and research method.